Published in Case Rep Hematol on July 12, 2011
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med (1997) 2.73
Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol (2009) 2.52
Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol (2003) 1.74
Granulocytic sarcoma with breast and skin presentation: a report of a case successfully treated by local radiation and systemic chemotherapy. Acta Haematol (2000) 1.66
Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol (2000) 1.43
Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature. Am J Hematol (2006) 0.92
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol (2008) 1.71
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 1.66
Questionable validity of cardiac risk score on the basis of the NSABP B-31 model. J Clin Oncol (2013) 1.39
The extra cytoplasmic function sigma factor sigma(E) is essential for Mycobacterium tuberculosis virulence in mice. Infect Immun (2004) 1.37
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology (2012) 1.23
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. ScientificWorldJournal (2010) 1.21
Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One (2013) 1.14
Thyroid metastasis of clear cell renal carcinoma: Report of a case. Diagn Cytopathol (2009) 1.13
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Pseudotumoral appearance of peliosis hepatis. AJR Am J Roentgenol (2005) 1.02
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol (2004) 1.01
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer (2013) 1.00
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys (2006) 1.00
Spindle-cell tumours of the larynx: diagnostic pitfalls. A case report and review of the literature. Acta Otolaryngol (2003) 1.00
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood (2003) 0.98
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics (2009) 0.96
Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One (2013) 0.93
Peritoneal carcinomatosis of colorectal origin. World J Gastrointest Oncol (2010) 0.92
Applications of genomics in NSCLC. Lung Cancer (2005) 0.90
Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev (2009) 0.89
Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol (2011) 0.87
FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer (2013) 0.87
Diffuse intra-abdominal clear cell myomelanocytic tumor: report of an unusual presentation of "PEComatosis" simulating peritoneal mesothelioma. Ann Diagn Pathol (2006) 0.87
Detection of human papillomavirus in temporal bone inverted papilloma by polymerase chain reaction. Acta Otolaryngol (2003) 0.86
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br J Haematol (2010) 0.86
Dasatinib induces a response in chronic lymphocytic leukemia. Blood (2009) 0.86
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncol (2013) 0.84
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip (2013) 0.84
Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine (2004) 0.83
Squamous cell carcinoma of the larynx with osteosarcoma-like stromal metaplasia. Acta Otolaryngol (2004) 0.83
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance. Cancer Invest (2008) 0.82
Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res (2006) 0.82
Malignant perivascular epithelioid cell tumor of the esophagus. Case Rep Pathol (2012) 0.82
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. J Neurooncol (2008) 0.82
Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions. Is curative irradiation feasible? Final results of a prospective study. Lung Cancer (2002) 0.81
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Rev Respir Med (2011) 0.81
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. Clin Exp Med (2014) 0.81
Risk of second malignant neoplasm among patients with lymphoma. J Clin Oncol (2011) 0.80
Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm Res (2007) 0.80
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer (2012) 0.80
Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine (2003) 0.80
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide. J Neurooncol (2007) 0.80
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. Hormones (Athens) (2013) 0.79
Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders. Neurobiol Dis (2013) 0.79
How cells respond to interferons. J Clin Oncol (2010) 0.79
Pitfalls of positron emission tomography for assessing relapse in Hodgkin's disease: a case report. Haematologica (2006) 0.79
Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol (2004) 0.78
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 0.78
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. J Neurooncol (2008) 0.78
Hypoglycemic syndrome in a patient with proinsulin-only secreting pancreatic adenoma (proinsulinoma). Case Rep Med (2011) 0.77
Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med (2015) 0.77
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. Leuk Res (2009) 0.77
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation. J Thorac Cardiovasc Surg (2006) 0.77
A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report. J Thorac Dis (2010) 0.76
Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. Future Oncol (2015) 0.76
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response? Leuk Res (2006) 0.76
From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol (2006) 0.76
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. Dig Liver Dis (2013) 0.75
Gene expression profiling does not identify molecular subgroup among nodal peripheral T-cell lymphomas. J Clin Oncol (2007) 0.75
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer (2004) 0.75
Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell Lymphoma. Case Rep Hematol (2012) 0.75
Interleukin-2 and lymphokine-activated killer cell therapy in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res (2007) 0.75
Castleman's disease as an uncommon cause of a neck mass. Acta Otolaryngol (2006) 0.75
Circulating mitotic figures in a patient with dual infection by Epstein-Barr virus and cytomegalovirus. Eur J Haematol (2013) 0.75
Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. Br J Haematol (2006) 0.75
Fatal delayed diagnosis in a patient with Falciparum malaria. Haematologica (2004) 0.75
Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine (2002) 0.75
An acute-leukaemia-like picture due to breast carcinoma cells. Lancet Oncol (2006) 0.75
An accessory spleen wrongly recognised as relapse by positron emission tomography. Eur J Haematol (2006) 0.75
Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab. Br J Haematol (2003) 0.75